Navigation Links
Chinese pharma-biotech dragon rears its head

- I am on the eve of departing for Osaka, Japan, for the Bio Japan 2006 conference as part of a small Illinois mission. I have written a number of times over the years about both the Japanese pharma and biotech industries, but I haven't been back to Japan for a few years and I'm looking forward to getting up to speed on t......

Full article >>> forward aggressively to implement common drug development parameters existing in countries such as the U.S. and Europe; in September 2003, they put into place Good Clinical Practice (GCP) standards. This measure alone has significant impact on the performance of clinical trials in China in a manner consistent with world-class standards.

The impact of GCP means not only the potential usabi......

Full article >>> cation.

According to a Sept. 1 article of Genetic Engineering News on "Chinese Biogenerics," 95 percent of Chinese pharmaceutical products are generic. As patents now are being implemented, however, the growth of the proprietary and innovative drugs is growing rapidly.

Before the 1990s, Chinese pharmaceutical companies were unable t......

Full article >>> up its deficiencies in patent law beginning with the September 2002 "Regulations for Implementation of the Drug Administration Law," which modified the definition of a new drug to that of a drug that never been marketed or sold previously in China) Furthermore, China's patent law was amended on December 12, 2002 to harmonize China's patent system with other WTO countries.

China will have ......

Full article >>> Pharmaceutical.

Hangzhou Jiuyuan Gene Engineering.

Hualan Biological Engineering.

NCPC Genetech Biotechnology.

Source: "Chinese Biogenerics," Genetic Engineering News, Sept. 1, 2006.

Chinese biogeneric companies have focused their efforts to date on such drugs as interferon, interleukins, GM-CMF, Erythropoetin (EPO), Hepatitis B vaccine, and re......

Full article >>> t shines among best hospitals in U.S.

Michael Rosen: The world of in-vitro diagnostics is another Midwest success story

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/22/2017)... 2017  PrimeVax Immuno-Oncology, Inc. announced today its CEO, ... Annual Biocom Global Life Science Partnering Conference.  The presentation ... at the Torrey Pines Lodge, in San Diego.  ... Biocom who have chosen our company, amongst numerous others, ... investors, and clinical researchers," said Mr. Chen. "In contrast ...
(Date:2/22/2017)... ... February 22, 2017 , ... ProMIS Neurosciences ... treatments for neurodegenerative diseases, today announced it has issued a scientific white paper ... one of a series of commentaries from ProMIS’s scientific team offering insight into ...
(Date:2/22/2017)... , Feb 22, 2017 ... of the "Global Biological Crop Protection (Bio-Pesticide) Market-By Type, By ... (2016-2021)" report to their offering. ... Global Biological Crop Protection Market is forecasted ... The strong growth in biopesticide or biological crop protection market ...
(Date:2/22/2017)... ... February 22, 2017 , ... NDA Partners ... MD former Acting Deputy Director in the FDA CDRH Division of Cardiovascular, Respiratory, ... joined the company as an Expert Consultant. , In Dr. Spyker’s accomplished career, ...
Breaking Biology Technology:
(Date:2/8/2017)... -- Aware, Inc. (NASDAQ: AWRE ), a leading supplier ... its quarter and year ended December 31, 2016. ... million compared to $6.9 million in the same quarter last ... $0.6 million compared to $2.6 million in the fourth quarter ... was $0.5 million, or $0.02 per diluted share, which compares ...
(Date:2/7/2017)... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ... at the LEERINK Partners 6th Annual Global Healthcare Conference ... February 15, 2017 at 10 a.m. Eastern Time. ... be accessed at http://wsw.com/webcast/leerink28/zbh .  The webcast will ... Biomet,s Investor Relations website at http://investor.zimmerbiomet.com . ...
(Date:2/2/2017)... Feb. 2, 2017   TapImmune, Inc. ... company specializing in the development of innovative peptide ... of cancer and metastatic disease, announced today it ... manufacturing of a second clinical lot of TPIV ... receptor alpha. The manufactured vaccine product will be ...
Breaking Biology News(10 mins):